A Research Resource for Ultra-sensitive High Throughput Proteomics - Community Engagement

项目摘要-社区参与 基于质谱（MS）的蛋白质组学在生物医学研究中的应用和影响预计将 由于开发的先进蛋白质组学平台的速度和有效性， 在这一资源的更新中，越来越多的实验室和临床站点比现在使用。的 蛋白质组学技术和相关能力的预计进展将包括能够使用 更小的样本量，提供比目前可行的更大的测量吞吐量，以及 因此成本低得多。这将为新的生物医学和临床应用提供基础， 蛋白质组学，预计将导致重要的新的生物医学的理解和见解。实现 这些目标在这最后的更新期，蛋白质组学研究资源不仅将提供进步， 这将大大增加蛋白质组学的能力和实用性，但也将与 独特的社区参与（CE）和传播活动，以实现其更大的 对生物医学研究和临床实践的影响，旨在确保广泛和持续的获取 新的能力。除了行政长官主办的讲习班和培训等传统机制外， 事件，以及资源驱动生物医学项目（DBP）所包含的基线机制 以及协作和服务工作、出版物、演示文稿等，除此之外，还将努力 加快资源的蛋白质组学进展的广泛可用性。这些努力将涉及：（1）直接 在其他合适的实验室的早期阶段“播种”来自蛋白质组学资源的关键技术 具有有效弥合“技术开发与应用之间差距”的记录;以及（2）在 同时，促进资源技术的早期商业实施，因为这是迄今为止最重要的 建立有效机制，确保广泛提供和持续获取这些平台进展。后一 通过将资源SLIM IM-MS技术（见TR&D 2）许可给 公司成立的目的是与MS平台供应商广泛合作，通过广泛的（即非 独家）技术的分许可，以鼓励和加快商业实施。 打开这条商业化道路，将推动最广泛的传播， 可能获得资源开发技术，并以预期提供 不同供应商MS技术平台的独特优势。总体而言，这种多管齐下的方法融合了 培训、研讨会和直接早期参与DBPs等更传统的外展工作 和其他合作，这些独特的传播努力，为最广泛和 最持久的先进蛋白质组学技术的可用性及其产生的生物医学影响。

Project Summary – Community Engagement The use and impacts of mass spectrometry (MS)-based proteomics in biomedical research are anticipated to expand significantly as a result of the speed and effectiveness of the advanced proteomics platforms developed in this Resource's renewal, becoming used by vastly more laboratories and clinical sites than at present. The projected advancements in proteomic technologies and related capabilities will include enabling the use of much smaller sample sizes and providing much greater measurement throughput than presently feasible, and hence at much lower costs. This will provide the basis for new biomedical and clinical applications of proteomics that are anticipated to result in important new biomedical understandings and insights. To achieve these objectives in this final renewal period the Proteomics Research Resource will not only provide advances that will greatly increase the power and utility of proteomics, but will also do this in conjunction with distinctive community engagement (CE) and dissemination activities necessary for realizing their much greater impacts upon biomedical research and clinical practice that are designed to assure broad and sustained access to the new capabilities. In addition to the conventional mechanisms of CE sponsored workshops and training events, as well as the baseline mechanisms encompassed by the Resource's Driving Biomedical Projects (DBPs) and collaborative and service efforts, publications, presentations, etc., these will be complemented by efforts to speed the broad availability of the Resource's proteomics advances. These efforts will involve: (1) directly `seeding' the key technologies from the Proteomics Resource at an early-stage in other suitable laboratories with a record of being effective in bridging the `technology development-to-application gap'; and (2) working in parallel to facilitate early commercial implementation of the Resource's technology, as this is by far the most effective mechanism to assure broad availability and sustained access to such platform advances. This latter mechanism has been initiated by the licensing of the Resource SLIM IM-MS technology (see TR&D 2) to a company established with the intent of working broadly with MS platform vendors, through wide (i.e. non- exclusive) sub-licensing of the technology, to encourage and speed commercial implementations. Opening this commercialization path will drive the broadest possible dissemination and yield the widest possible access to the Resource developed technologies, and do so in a manner anticipated to provide the unique benefits of the different vendor MS technology platforms. Overall this multi-pronged approach melds the more conventional outreach efforts of training, workshops, and the direct early engagement in the DBPs and other collaborations, with these distinctive dissemination efforts to provide the basis for the broadest and most sustained availability of the advanced proteomics technologies and their resulting biomedical impacts.